![Lior Shaltiel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lior Shaltiel
Vorstandsvorsitzender bei
NUREXONE BIOLOGIC INC.
Vermögen: 166 600 $ am 30.06.2026
Profil
Lior Shaltiel currently works at NurExone Biologic, Inc., as Chief Executive Officer & Director from 2022, NurExone Biologic Ltd., as Chief Executive Officer & Director from 2021, and The Hebrew University of Jerusalem, as Head-BioMed MBA Program from 2015.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NUREXONE BIOLOGIC INC 0,46 % | 27.11.2025 | 425 000 ( 0,46 % ) | 166 600 $ | 30.06.2026 |
Aktive Positionen von Lior Shaltiel
| Unternehmen | Position | Beginn |
|---|---|---|
| NUREXONE BIOLOGIC INC. | Vorstandsvorsitzender | 01.04.2021 |
NurExone Biologic Ltd.
 NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Vorstandsvorsitzender | 01.04.2021 |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.10.2015 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
54
Beziehungen ersten Grades
3
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
The Hebrew University of Jerusalem
The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NurExone Biologic Ltd.
NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
NurExone Biologic, Inc.
 NurExone Biologic, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury | Health Technology |
Wählen Sie MarketScreener 
